About Page

 

WELCOME TO ANGIO360DX

 

Angio360 Diagnostics, LLC is a privately held pre-development company specializing in antibody-based products focused on improving the detection and treatment of canine and human cancers.

Utilizing patented biomarkers uniquely associated with tumor angiogenesis (cancer blood vessel growth), Angio360’s mission is to provide innovative and non-invasive cancer monitoring tools for veterinarian and human oncologists to effectively diagnose and monitor cancer treatment for all cancer patients. Application of these tools will allow for more precise and efficient treatments, thus reducing the overall cost of care and improving patient outcomes.


WE ARE ANGIO360

Our ultimate goal is to create and sell valuable diagnostic products to help improve lives through reducing healthcare costs and improving patient outcomes. 

Our mission is to provide innovative and non-invasive cancer monitoring tools for veterinarian and human oncologists to effectively diagnose and monitor cancer treatment for all cancer patients. 

OUR PRODUCTS

Angio360 is developing diagnostic products for two different markets; the veterinary oncology market and human oncology market. Currently, as cancer treatments for companion animals becomes more prevalent, there is a growing demand for non-invasive oncology diagnostic tools in the veterinary market. For the human oncology market, there is a large unmet need for simple diagnostic methods for assessing cancer treatment efficacy and tumor recurrence in neurological-based cancers, such as gliomas and other types of cancers in which there is currently a lack of reliable blood tumor biomarkers. 

INTERESTED IN INVESTING?

WANT MORE INFORMATION?

Layout Style

Direction

Predefined Colors

Background